Joint Action on HIV and co-infection prevention and harm reduction HA-REACT
|
|
- Theodora Richards
- 5 years ago
- Views:
Transcription
1 Joint Action on HIV and co-infection prevention and harm reduction HA-REACT Principles and challenges of HA-REACT as an example of multilateral and multisectoral programme Mika Salminen, Ph. D, Research Professor Outi Karvonen, Project Manager 19 September 2017, St. Petersburg
2 HIV diagnoses acquired through injecting drug use, 2014, EU/EEA Rate per population < 1 1 to <3 3 to <5 > 5 Not included or not reporting Non-visible countries Liechtenstein Luxembourg Malta Source: ECDC/WHO (2015). HIV/AIDS Surveillance in Europe, 2014
3 1240 new HIV diagnoses among PWID in cases in Denmark, Norway, Finland <5 cases in Czech Republic, Slovakia, Croatia, Hungary, Cyprus, Netherlands, Slovenia, Iceland Source: ECDC/WHO (Nov 2016) Source: PRELIMINARY DATA ECDC/WHO (SoS2016)
4 TB among people who use drugs No statistical data easily available; WHO Global database: 13 from 31 EU/EEA countries reported 450 intravenous drug users (2%) among approx TB cases in the respective countries in 2016; Link: drug use HIV infection co-infection HIV/TB; Experiences and guidance prepared by the TUBIDU project used in the HA-REACT Joint Action. Empowering the public health system and civil society to fight the tuberculosis epidemic among vulnerable groups. Desk review; Handbook for community based organisations on tuberculosis services for people who inject drugs; Training outline for trainings based on TUBIDU Handbook
5 TB among people who use drugs
6
7 9 Seven key recommended interventions COMBINE THESE KEY INTERVENTIONS TO ENHANCE PREVENTION SYNERGY AND EFFECTIVENESS INJECTION EQUIPMENT: Provision of and legal access to clean drug injection equipment, including sufficient supply of sterile needles and syringes, free of charge, as part of a combined multicomponent approach, implemented through harmreduction, counselling and treatment programmes VACCINATION: hepatitis A and B, tetanus, influenza vaccines, and, in particular for HIV-positive individuals, pneumococcal vaccine DRUG DEPENDENCE TREATMENT: Opioid substitution treatment and other effective forms of drug treatment TESTING: Voluntary diagnostic testing with informed consent for HIV, HCV, (HBV for unvaccinated) and other infections including TB should be routinely offered and linked to referral to treatment INFECTIOUS DISEASE TREATMENT: Antiviral treatment based on clinical indications for those who are HIV, HBV or HCV-infected. Antituberculosis treatment for active TB cases. TB prophylactic therapy should be considered for latent TB cases. HEALTH PROMOTION: health promotion focused on safer injecting behaviour; sexual health including condom use; and disease prevention, testing and treatment TARGETED DELIVERY OF SERVICES: Services should be combined and organised and delivered according to user needs and local conditions; this includes the provision of services through fixed sites offering drug treatment, harm reduction, counselling and testing, and referrals to general primary health and specialist medical services.
8 Basic facts The HA-REACT Joint action is based on: Communication from the Commission [COM(2009)569] on Combating HIV/AIDS in the European Union and neighbouring countries, Commission [SWD(2014)106] Action plan on HIV/AIDS in the EU and neighbouring countries
9 Basic facts (2) HA-REACT Budget: approx. 3,75 million EUR co-funding by EC 80% Duration: October 2015 September 2018 Coordination: National Institute for Health and Welfare (THL), Finland Partners: 22 partners from 18 countries
10 Geographical coverage of HA-REACT
11 HIV trend HIV case reports and prevalence (15% weight; no increase in case reports or prevalence=0; increase in one=1; increase in both=2; high without an increase=1) Focusing the action: use of ECDC and EMCDDA objective selection criteria Table 1: Indicators of HIV trend, transmission risk and prevention coverage AT BE BG HR CY CZ DK EE FI FR DE EL HU IS IE IT LV LT LU MT NL NO PL PT RO SK SI ES SE UK Transmission risk prevalence of injecting drug use, changes in injecting risk behaviour (HCV prevalence and trends) (10% weight; no changes=0; moderate increase in one criteria=1; increase in >1 criteria=2) OST coverage % estimated problem opiate user population receiving OST (cut-off 30%) (25% weight; OST coverage >30%=0; no data=1; OST coverage <30%=2) NSP coverage Number of syringes given out per PWID per year (cut-off 100 syringes) (25% weight; NSP coverage >100=0; no data=1; NSP coverage<100=2) Taking part in the Joint Action x x x x x x x x x x x x x x x x x x x x Scores (maximum 2) 0, 3 0, , 6 0 0, 5 0,6 0, 3 0, 3 0, 3 0,9 1,2 0, 5 Ranking of those participating in the JA (1=greatest need/opportunity to improve harm reduction situation) NO ALERT no evidence for increase in case reports or HIV/HCV prevalence and/or transmission risk and/or low intervention coverage 0, 3 0, 3 1,5 0, 9 0 0, 3 0, 3 0 0,8 0,5 1, 3 CONCERN - Subnational increase in HIV/HCV prevalence and/or transmission risk or consistent but non-significant rise at national level. ALERT evidence for significant increase in case reports or HIV/HCV prevalence and/or increase in transmission risk and/or low intervention coverage. Information unknown/not reported to EMCDDA/ECDC. 1 0, 3 0 0, 5 0, 3 Mika Salminen/Outi Karvonen 9
12 Planning of the HA-REACT Joint Action Background concept paper from the European Commission (commented by the EU HIV/AIDS Think Tank) Support from NDPHS Expert Group on HIV, TB and Associated Infections Logical Framework Approach as a planning tool Based on the analysis of problems and development needs of the beneficiaries Participatory approach listening to professionals from Focus countries: Latvia, Lithuania and Hungary (both government organisations and NGOs) Aiming at sustainability To bring added value to the whole EU, not only Focus countries
13 Planning meetings Logical Framework Approach workshops during spring 2016: WP4 Testing and linkage to care, Budapest, February WP8 Sustainability and long-term funding, Riga, March WP5 Scaling up harm reduction, Vilnius, March WP6 Harm reduction and continuity of care in prisons, Prague, April WP7 Integrated care, Tallinn, April
14 Objectives of HA-REACT Zero new HIV cases, reduced HCV and TB among PWID in the EU by 2020 Improved prevention and treatment of blood-borne infections and TB in priority regions and priority groups in the European Union Purpose Improved capacity to respond to HIV and co-infection risks and provide harm reduction with specific focus on people who inject drugs (PWID) in the EU Direct beneficiaries: professionals working with PWID Ultimate beneficiaries: people who inject drugs
15 Zero new HIV, reduced HCV and TB among PWID in the EU by 2020 Improved prevention and treatment of blood-borne infections and TB in priority regions and priority groups in the European Union Improved capacity to respond to HIV and co-infection risks and provide harm reduction with specific focus on people who inject drugs (PWID) in EU 0. Management Work Package 4 Work Package 5 Work Package 6 Work Package 7 Work Package 8 0. Admin and management of the Joint Action 1. Improved early diagnosis of HIV, viral hepatitis and TB, as well as improve d linkage to care for PWID 2. Harm reduction scaled up in EU based on Latvian and Lithuanian cases 3. Increased harm reduction and improved continuity of care for PWID in prison settings 4. Improved provision of integrated HIV, HCV, TB treatment and harm reduction for PWID 5. National programmes updated to overcome barriers to respond to HIV, TB and HCV-related needs of PWID in the EU, specifically in the focus countries Structure and objectives of the Joint Action
16 HA-REACT Work Packages and their leadership WP1. Coordination THL, Finland WP2. Dissemination CHIP, Denmark WP3. Evaluation UKE ZIS, Hamburg WP4. Testing and linkage to care DAH, Berlin WP5. Scaling up harm reduction CIBER (ISCIII), Spain WP6. Harm reduction and continuity of care in prisons ISFF, Frankfurt WP7. Integrated care NIHD, Estonia WP8 Sustainability and long-term funding CHIP, Denmark
17 Advisory Board CHAFEA DG SANTE DG HOME ECDC EMCDDA WHO/EURO Civil Society Forum on Drugs /Correlation network Civil Society Forum on HIV/AIDS European network of people who use drugs (EuroNPUD) Eurasian Harm Reduction Network (EHRN) European Association for the Study of the Liver (EASL) European Liver Patients Association (ELPA) NDPHS Expert Group on HIV, TB and Associated Infections UNODC European Forum for Primary Care (EFPC)
18 Activities so far 1st Steering Committee in Luxembourg, 8-9 December 2015 Kick-off in Vilnius, 14 January Advisory Board meetings (Vilnius and Riga) 5 Steering Committee meetings Partnership Forum in Riga, November 2016 CHAFEA Symposium in Malta, January 2017
19 WP4 objectives Testing and linkage to care Improved early diagnosis of HIV, viral hepatitis and TB, as well as improved linkage to care for PWID 1.Personnel working with PWID in Hungary and Latvia trained in low-threshold testing of HIV, HCV 2.An interactive training manual and e-learning package on HIV and HCV testing in low threshold settings for personnel who work with people who use drugs, with special focus on women and peers, developed. 3.Awareness of clients of their infection status, of prevention and treatment of HIV, HCV and TB, improved. 4. Access to treatment after positive test result is ensured. 5. Gender-specific approach in testing services focused on women who use drugs developed and implemented.
20 WP4 activities so far WP4 Testing and linkage to care Improved early diagnosis of HIV, viral hepatitis and TB, as well as improved linkage to care for PWID Training on HIV/HCV testing November 15-17, 2016, Latvia December 13-15, 2016, Hungary May 23-25, 2917, Latvia Leaflets and posters developed to encourage PWID to take rapid HIV and HCV tests (Lv, Hu, Eng, Ru) Training manual and e-learning tool started.
21 Leaflets and posters to promote HIV/HCV tests
22 WP5 objectives Harm reduction Harm reduction scaled up in EU based on Latvian and Lithuanian cases 1.PWID epidemiology and harm reduction interventions assessed in Latvia and Lithuania 2.Training package to care providers and policy makers on HR interventions developed and implemented 3. Harm reduction interventions implemented in Latvia and Lithuania
23 WP5 activities so far Country mission implemented: Regular meetings in Focus Countries (January, February, April and June) and by skype to determine general situation in the countries, main barriers and necessities. Jan 2015
24 WP5 activities so far (2) WP5 Scaling up harm reduction Harm reduction scaled up in EU based on Latvian and Lithuanian cases Seminars for Debate in Vilnius and Riga, April Analysis of : - successful experiences in other countries - legal framework for the scale-up of HR: fully developed. - Political will toward harm reduction, - drug policy and HIV/AIDS - Role of private sector: - need to be involved (Lt) Study visits for participants from Latvia (October 2016) and Lithuania (September 2017), to Madrid and Barcelona Study visit to Prague, April, 2017
25 WP5 activities so far (3) WP5 Scaling up harm reduction Mobile unit as a low-threshold service for drug users started in January 2017 in Riga Nurse, outreach worker, social worker 23 hours per week Needle and syringe exchange -Testing on HIV, hep B, hep C, and syphilis - Condoms - TB consulting -Social and peer counselling
26 WP6 objectives Prison settings Increased harm reduction and improved continuity of care for PWID in prison settings 1.Situation analysis / mapping of needed support in the participating countries implemented 2.Medical, social and other prison professionals trained to work with PWID and to provide harm reduction services (incl. OST, NSP, condom provision and psychological support) 3. IEC materials developed for PWID and staff in prisons 4. Practical toolkit for harm reduction in prisons made available 5. Condom provision and other harm reduction measures piloted in one prison 6. Policy brief developed based on experiences from the component
27 WP6 activities so far WP6 Prison settings Increased harm reduction and improved continuity of care for PWID in prison settings E-learning modules developed for prison Study tour for prison staff from Czech Republic to Berlin (October 6-7, 2016) Pilot prison chosen in Prague and distribution of condoms started; International seminar on harm reduction in prisons, Warsaw, March, participants
28 WP6 activities so far (3) WP6 Prison settings Needle exchange and other harm reduction measures in prison settings workshop in Luxembourg, June, 2017 Approx. 60 participants from 14 countries Visit to Schrassig prison
29 WP7 objectives Integrated care Improved provision of integrated HIV, HCV, TB treatment and harm reduction for PWID 1.Capacity of health, social and civil society professionals in providing better quality of care for PWID improved 2.Evidence- and practice- based tools and instructional materials developed and provided for implementation of better quality care for PWID
30 WP7 activities so far WP7 Integrated care Improved provision of integrated HIV, HCV, TB treatment and harm reduction for people who inject drugs International workshop on building a platform for integrated care, 5 April, 2017, Vilnius (Lithuania) overview of different approaches to integrating care for people who inject drugs and highlight how these necessitate new roles, responsibilities, skills and competencies (Lithuania, United Kingdom) overview of good practices of integrated care from the countries already implementing effective solutions (Spain, Portugal, Germany, United Kingdom (including Scotland) reflections on patients experiences, needs and expectations and how to involve patients and community in developing services for PWID (Estonia, Portugal) Mapping report of existing guidelines on quality of care and different models of care under preparation.
31 WP8 objectives Sustainability and long-term funding National programmes updated to overcome barriers to respond to HIV, TB and HCV-related needs of PWID in the EU, specifically in the focus countries (WP8) 1.Strategies for national AIDS programmes for planning resource mobilisation, allocation and financial sustainability for activities addressing HIV-related needs of PWID suggested 2.Strategies for removing provider-dependant barriers in access to highquality HIV, co-infection and harm reduction services to PWID mapped, analysed and proposed 3.Strategies for removing customer-dependant barriers in access to highquality HIV, co-infection and harm reduction services to PWID mapped, analysed and proposed 4. Strategies for removing structural barriers in access to high-quality HIV, hepatitis and TB services to PWID mapped, analysed and proposed
32 WP8 activities so far WP8 Sustainability and long-term funding National programmes updated to overcome barriers to respond to HIV, TB and HCV-related needs of PWID in the EU, specifically in the focus countries HA-REACT Sustainable Funding meeting in October 26, 2016, Budapest (Hungary) Meeting on financing and sustainability of harm reduction services on 6 April, 2017, Vilnius (Lithuania) Literature review, policy review and survey under preparation Guidance on funding mechanisms drafted.
33 Next activities National workshops on models of care to be organized in Lithuania (7 September), Czech Republic (16 October) and Estonia (30 August), Hungary (to be confirmed); Training workshop on harm reduction interventions, Lithuania (October); Training on TB, gender-specific approach in testing and harm reduction interventions for NGOs in December 2017 (Budapest, to be confirmed) Harm reduction for people who inject drugs in Europe: findings from three major European projects session at the Addictions Conference in Lisbon, 25 th October Partnership Forum on October in Lisbon Advisory Board on the 26 th Steering Committee on the 26 th Training of trainers workshop on harm reduction in prisons, Poland (November).
34 Challenges 22 partner organisations; 18 countries different languages and cultures; Different attitudes towards harm reduction and people who inject drugs; Political changes; Merging of two partners into the Ministry of Human Capacities in Hungary; Problems with rapid HIV and HCV testing in low-threshold settings in Lithuania new legal acts; Bureaucracy of the EU grant system; Inevitable amendments to the grant agreement; Guidance of partners who have not earlier participated in large EU projects; Division of tasks, keeping timelines; Coordinating with other projects and programmes; Ensuring sustainability.
35 HA-REACT blog series Featured on the BioMed Central On Health blog and the Hepatology, Medicine and Policy (HMAP) blog Structured as interviews with Jeffrey Lazarus as WP2 lead & SC member Focuses on individual WPs Spotlights partners & their work Promotes HA-REACT Ongoing (8 published todate)
36 More information available: #HAREACT Project Manager Outi Karvonen, WP2 Dissemination and WP8 lead Jeffrey Lazarus,
37 Website developed and hosted by AIDS Action Europe #HAREAC T
HIV/AIDS Joint Action HA-REACT
HIV/AIDS Joint Action HA-REACT Matthias Schuppe Policy Officer Health Threats Unit DG Health and Food Safety European Commission Policy Framework on HIV/AIDS in EU and neighbouring countries Commission
More informationHA-REACT Joint Action on HIV and coinfection. prevention and harm reduction
HA-REACT Joint Action on HIV and coinfection prevention and harm reduction 3 rd EU Health Programme Call: HP-JA-2014, Topic: JA-02-2014 9.4.2015 Mika Salminen/Outi Karvonen 1 A proposal for a Joint Action
More informationNew trends in harm reduction in Europe: progress made challenges ahead
New trends in harm reduction in Europe: progress made challenges ahead Dagmar Hedrich, Alessandro Pirona, EMCDDA 2 nd European Harm Reduction Conference, 7-9 May 2014, Basel Session 4: Changes in harm
More informationANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)
ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft) Project Title: HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Project Number: XEEJ20 Total
More informationTrends in injecting drug use in Europe
Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information
More informationNDPHS Expert Group on HIV/AIDS and Associated Infections Progress report 27 October, Chair Dr. Ali Arsalo and ITA Ms Outi Karvonen
NDPHS Expert Group on HIV/AIDS and Associated Infections Progress report 27 October, 2011 Chair Dr. Ali Arsalo and ITA Ms Outi Karvonen NDPHS Goals for the HIV/AIDS & AI Expert Group Goal 2: Prevention
More informationSpreading Excellence and Widening Participation
Spreading Excellence and Widening Participation Dr G Ambroziewicz Ankara, 27/02/2017 Research and Background Disparities in research and innovation performance: barrier to competitiveness, growth and jobs
More informationPublic administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective
Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government
More informationECDC and Spanish Ministry of Health workshop:
ECDC and Spanish Ministry of Health workshop: Improving the monitoring of HIV among migrant populations in Europe, Madrid, 3-4 October 2013 Teymur Noori EU Commission Thank Tank on HIV/AIDS Luxembourg,
More informationFeedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014
Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014 Dr. Nicole Werner-Keišs Lisbon, 16.10.2014 Outline Background, scope and objectives
More informationThe Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC
The Comprehensive Package: The simple truth about our response to drug related HIV Dr. Monica Beg, Signe Rotberga UNODC HIV among injecting drug users Why is it so important? 30% global HIV infections
More informationEMCDDA-update HIV/HCV among people who inject drugs: situation and response
EMCDDA-update HIV/HCV among people who inject drugs: situation and response Dagmar Hedrich EU Think Tank HIV/AIDS: 24-25 November 2015, Luxembourg Latest European overview Multi-indicator based analysis
More informationNew EU Health Programme: funding mechanisms for civil society working on HIV and related areas
New EU Health Programme: funding mechanisms for civil society working on HIV and related areas Cinthia Menel Lemos Think Tank meeting Luxembourg, 10 December 2013 Executive Agency for Health and Consumers
More informationScreening programmes for Hepatitis B/C in Europe
Programme STI, HIV/AIDS and viral hepatitis Screening programmes for Hepatitis B/C in Europe Mika Salminen, Ph.D. European Centre for Disease Prevention and Control Why might screening be needed for hepatitis
More informationEMPOWERING CIVIL SOCIETY AND PUBLIC HEALTH SYSTEM TO FIGHT TUBERCULOSIS EPIDEMIC AMONG VULNERABLE GROUPS
EMPOWERING CIVIL SOCIETY AND PUBLIC HEALTH SYSTEM TO FIGHT TUBERCULOSIS EPIDEMIC AMONG VULNERABLE GROUPS Cinthia Menel Lemos cinthia.menel-lemos@ec.europa.eu Project Officer Executive Agency for Health
More informationEmerging epidemics: Will they derail progress? Eastern/Central Europe
Emerging epidemics: Will they derail progress? Eastern/Central Europe Marieta Simonova, MD Clinic of Gastroenterology, Military Medical Academy Sofia, Bulgaria Disclosures Speaker/Adviser for AbbVie, Gilead,
More informationTransmission, processing and publication of HBS 2015 data
EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Unit F-4: Income and living conditions; Quality of life Doc. LC-ILC/194/17/EN estat.f.4 (2017) WORKING GROUP ON INCOME AND LIVING CONDITIONS
More informationepidemic among vulnerable groups
Project TUBIDU Empowering public health system and civil society to fight tuberculosis epidemic among vulnerable groups Prepared by: Aljona Kurbatova, NIHD Maarja Sukles, NIHD Liga Rusmane, LTBF What is
More informationTajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan
HARM REDUCTION WORKS FUND IT! National Report Summary Arguments for strategic investment With the support of The present document contains a summary of the key conclusions and recommendations provided
More informationHIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications
HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications Don Des Jarlais, Ph.D. Professor of Psychiatry, Icahn School of Medicine at Mount Sinai UNODC 2014
More informationExtrapolation and potential impact of IPHS deployment in Europe
SIMPHS2 Validation Workshop Brussels, 31 Jan 2012 1 SIMPHS2 Validation Workshop Extrapolation and potential impact of IPHS deployment in Europe JRC IPTS IS Unit Ioannis Maghiros, Fabienne Abadie, Maria
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including this activity in the proposal The World Health Organization (WHO), the Joint United
More informationFormative Research results
FRR Annex 5: Presentation of the FR results in the project meeting, Berlin, 11. 13.02.2013 Formative Research results Sandra Dudareva Vizule, Ulrich Marcus Robert Koch Institute 11 February 2013 Content
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationFinnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
More informationGLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy
GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA The critical need to scale up opioid substitution therapy Craig McClure IAS Executive Director Outline of Presentation 1.
More informationMeeting report, September 2005
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 24 October 2005 Doc. Ref. EMEA//322553/2005 COMMITTEE ON HERBAL MEDICINAL PRODUCTS () Meeting report, 19-20 September
More informationMonthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
More informationImplementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2010 Progress Report SPECIAL REPORT.
SPECIAL REPORT Implementing the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2010 Progress Report Summary www.ecdc.europa.eu ECDC SPECIAL REPORT Implementing the Dublin
More informationDrug Consumption Rooms Worldwide
Drug Consumption Rooms Worldwide Eberhard Schatz Correlation Network International Network of Drug Consumption Rooms Introduction Overview of the current state of DCR s worldwide Presentation of the INDCR
More informationMinutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012, Luxembourg
EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C4 - Health determinants Minutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012,
More informationPalliative nursing care of children and young people across Europe
Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)
More informationProject Meeting Prague
Project Meeting Prague IO1 Assessment 9.11.217 CHRISTINA PADBERG ON BEHALF OF FRANKFURT UAS Current Status Assessment matrix was fully evaluated Experts have been interviewed, Interviews were fully evaluated
More information'SECTION B EU PARTY. The following abbreviations are used:
'SECTION B EU PARTY The following abbreviations are used: AT Austria BE Belgium BG Bulgaria CY Cyprus CZ Czech Republic DE Germany DK Denmark ES Spain EE Estonia EU European Union, including all its Member
More informationHIV testing in Europe: From policy to effectiveness
HIV testing in Europe: From policy to effectiveness 10 th Think Tank meeting Brussels, 9-10 April 2008 Françoise Hamers Scientific Advice Unit, ECDC ecdc.europa.eu Background About 30% of people living
More informationKey issues for HIV testing and
Key issues for HIV testing and counselling in Europe Martin C Donoghoe Programme Manager HIV/AIDS, STI &Viral Hepatitis Programme WHO Europe Key issues for HIV testing & counselling in Europe HIV epidemics
More informationAction Plan on HIV/AIDS in the EU and neighbouring countries:
Action Plan on HIV/AIDS in the EU and neighbouring countries: 2014-2016 Matthias Schuppe Policy Officer Health Threats Unit DG Health and Consumers European Commission Outline o EU policy framework on
More informationPrevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs
Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs Aljona Kurbatova National Institute for Health Development Estonia Estimated number of people who inject
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More information2 nd Meeting on detecting and responding to outbreaks of HIV among PWID
2 nd Meeting on detecting and responding to outbreaks of HIV among PWID Update on country situation: AUSTRIA Lisbon, 12 th October 201 Epidemiological update 2 HIV notifications in PWID Number of HIV cases
More information10/07/18. Dr. Otilia Mårdh, ECDC. No conflicts of interest.
No conflicts of interest. Prevention and control of chlamydia in Europe from data to policies and testing recommendations Dr. Otilia Mårdh, ECDC 15th Congress of the European Society of Contraception and
More informationECDC update to the EU Commission Think Tank on HIV/AIDS
ECDC update to the EU Commission Think Tank on HIV/AIDS Andrew Amato Head of HIV, STI and V. Hepatitis programme, ECDC Luxembourg, 10-11 December 2013 Outline Main ECDC reports published since last Think
More informationTable Of Content. Outputs... 8
Table Of Content Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Tervise
More informationReview of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes
Review of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes Report to ECOSTAT Martyn Kelly (Bowburn Consultancy, UK) Sebastian Birk (University of Duisburg-Essen,
More informationHepatitis and HIV Co-Infection: Situation in Ukraine.
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV Hepatitis and HIV Co-Infection: Situation in Ukraine. Pavlo Skala Associate Director: Policy & Partnership Ukraine
More informationSUMMARY OF INTERIM REPORT
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EXECUTIVE AGENCY FOR HEALTH AND CONSUMERS Health unit SUMMARY OF INTERIM REPORT Title: Empowering Civil Society and Public Health System to
More informationManuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal Public Health Public health is the science and art of preventing disease, prolonging
More informationFieldwork: February March 2010 Publication: October 2010
Special Eurobarometer 345 European Commission Mental Health Part 1: Report Fieldwork: February March 2010 Publication: October 2010 Special Eurobarometer 345 / Wave 73.2 TNS Opinion & Social This survey
More informationCOUNTRY REPORT: EPIDEMIOLOGICAL SITUATIONS AND PROJECT ACTIVITIES
COUNTRY REPORT: EPIDEMIOLOGICAL SITUATIONS AND PROJECT ACTIVITIES BIRUTE SEMENAITE, MEDICAL DIVISION OF PRISON DEPARTMENT AT THE MINISTRY OF JUSTICE OF THE REPUBLIC OF LITHUANIA LITHUANIAN PRISONS. BACKGROUND:
More informationHarm Reduction in Nigeria
Harm Reduction in Nigeria Needs, gaps, and responses to ensure access to effective HIV prevention, treatment and care for people who inject drugs February 2018 This document is made possible by the generous
More informationThe Nordic Council of Ministers (NCM) Co-operation with Northwest Russia
The Nordic Council of Ministers (NCM) Co-operation with Northwest Russia Thematic Programme for Health Promotion and Prevention - Mobilizing Resources for Better Response: Immunodeficiency virus and associated
More informationAlcohol Prevention Day
Alcohol Prevention Day Rome, 16 May 2018 Hana Horka Policy Officer, Unit C4 Health Determinants and International Relations European Commission DG Health and Food Safety (SANTE) Alcohol consumption in
More informationEUROPEAN CITIZENS DIGITAL HEALTH LITERACY
Flash Eurobarometer 404 EUROPEAN CITIZENS DIGITAL HEALTH LITERACY SUMMARY Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General
More informationECDC s role in the fight against HIV/AIDS in Europe
European Centre for Disease Prevention and Control ECDC s role in the fight against HIV/AIDS in Europe Marita van de Laar, PhD Program Coordinator HIV/AIDS, STI, hepatitis HIV in Europe, Stockholm, 2 November
More informationMid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006
Mid-term Review of the UNGASS Declaration of Commitment on HIV/AIDS Ireland 2006 Irish Role in Global Response Just as the HIV/AIDS epidemic is a global threat, addressing the challenge of the epidemic
More informationEuropean status report on alcohol and health Leadership, awareness and commitment
European status report on alcohol and health 2014 Leadership, awareness and commitment Leadership, awareness and commitment Background Strong leadership from national and local governments is essential
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
Ref. Ares(2015)2319265-03/06/2015 EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Directorate D - Health systems and products D4 Substances of Human Origin and Tobacco Control Brussels,
More informationUpdate on EEA s near real time air quality data exchange
Update on EEA s near real time air quality data exchange Jaume Targa (EEA ETC/ACC) Acknowledgement Thanks to all nrt data providers Currently there are 71 providers Latvian Environment, Geology and Name
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationHIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015
HIV/AIDS Think Tank meeting: EMCDDA report Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015 European Drug Report 2015 Drop o Trends in seizures by substance from 2009 o Drug and related long-term
More informationThe new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany
The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach Ines Perea Ministry of Health, Germany Reasons for a new strategy in 2016 New international agreements (SDG s) Renewed political
More informationNEEDLE AND SYRINGE PROGRAMMES MONITORING IN LITHUANIA
NEEDLE AND SYRINGE PROGRAMMES MONITORING IN LITHUANIA Dr. Audronė Astrauskienė Drug control department under the Government of the Republic of Lithuania 2010 10 25 Harm reduction services development in
More informationGlobal health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )
Regional Committee for Europe 65th session EUR/RC65/Inf.Doc./3 Vilnius, Lithuania, 14 17 September 2015 2 September 2015 150680 Provisional agenda item 3 ORIGINAL: ENGLISH Global health sector strategies
More informationStrategies of drug users to avoid infection with hepatitis C
With financial support from the Drug Prevention and Information Programme of the European Union Strategies of drug users to avoid infection with hepatitis C Results from five European countries Dr. Heike
More informationGlobal, regional and national strategic planning for viral hepatitis prevention and control
Global, regional and national strategic planning for viral hepatitis prevention and control Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Baltic Meeting 19 20 November 2015 Riga, Latvia Presentation
More informationTramadol-related deaths
Tramadol-related deaths 216 Survey overview European joint DRD expert meeting Lisbon, 29-3 September 216 Isabelle Giraudon, Federica Mathis, Klaudia Palczak Paralel workshop Opioids, medicines and focus
More informationEUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY
Ref. Ares(2016)5909621-13/10/2016 EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Directorate B - Health systems, medical products and innovation B4 Medical products: quality, safety
More information2 nd Meeting on detecting and responding to outbreaks of HIV among PWID
2 nd Meeting on detecting and responding to outbreaks of HIV among PWID Update on country situation: ROMANIA Adrian Abagiu* & Andrei Botescu** *Romanian Association Against AIDS (ARAS) and National Institute
More informationHepatitis prevention in the context of HIV prevention point work in Latvia
Hepatitis prevention in the context of HIV prevention point work in Latvia Līva Grāmatiņa Centre for disease prevention and control of Latvia 9..205. HIV prevention point network in Latvia: History; Location;
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationImproving NSP and Harm Reduction Services. Jason Farrell, European HCV and Drug Use Initiative
Improving NSP and Harm Reduction Services Jason Farrell, European HCV and Drug Use Initiative Presentation Overview With the growing need to treat HCV, NSP programs have been identified in numerous stakeholder
More informationYoung people and drugs. Analytical report
Flash Eurobarometer European Commission Young people and drugs among 15-24 year-olds Analytical report Fieldwork: May 2008 Report: May 2008 Flash Eurobarometer 233 The Gallup Organization This survey was
More informationWho is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers
HIV and migrants Julia del Amo has received research grants awarded to her institution from Companies BMS, Gilead, ViiV and epidemiology teaching fees from ViiV, Gilead and MSD Dr Julia del Amo National
More informationCross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
More informationTrichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
Annual Epidemiological Report for 2015 Trichinellosis Key facts In 2015, a total of 156 confirmed cases of trichinellosis was reported from 29 EU/EEA countries. The overall notification rate was 0.03 cases
More informationDrug-related infectious diseases
Drug-related infectious diseases Mike Catchpole Chief Scientist, European Centre for Disease Prevention and Control Tuesday 24th October 2017 Basic (Case) Reproduction Rate All you need to know to design
More informationBulgaria Bulgaria Drug Report 2018
Bulgaria Bulgaria Drug Report 218 This report presents the top-level overview of the drug phenomenon in Bulgaria, covering drug supply, use and public health problems as well as drug policy and responses.
More informationOverall aim Improving the access to and the quality of health and social services for marginalised people
Overall aim Improving the access to and the quality of health and social services for marginalised people To tackle health inequalities and to improve prevention, care and treatment services, targeting
More informationNSPs in Estonia: current situation and future challenges
NSPs in Estonia: current situation and future challenges Aljona Kurbatova National Institute for Health Development Riga, 25.10.2010 1 Background First NSP project was launched in May 1997 needle and syringe
More informationReport. Survey conducted by TNS political & social
Food waste and date marking Survey conducted by TNS political & social This document does not represent the point of view of the European Commission. The interpretations and opinions contained in it are
More informationWCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
More informationFIGHTING HIV IN ESTONIA IN 2006 AND Aire Trummal, Liilia Lõhmus, Kristi Rüütel
FIGHTING HIV IN ESTONIA IN 2006 AND 2007 Aire Trummal, Liilia Lõhmus, Kristi Rüütel Tallinn 2008 TABLE OF CONTENTS INTRODUCTION... 3 1. TRENDS OF HIV TRANSMISSION IN ESTONIA... 4 2. STRUCTURES FOR IMPLEMENTING
More informationWCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationImplementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO
Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationWCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
More informationEIIW Competitiveness Report on the EU Market
EIIW Competitiveness Report on the EU Market Jens K. Perret Wuppertal, January 215 Preliminary European Institute for International Economic Relations at the University of Wuppertal, Rainer-Gruenter-Str.
More informationFeedback on the first Widening Calls
Feedback on the first Widening Calls Some facts figures Dimitri Corpakis Head of Unit Spreading Excellence Widening Participation DG Research, European Commission Brussels, CPU Clora, 18/3/15 Criteria
More informationPerspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU
Perspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU N. Safrany European Commission Pr. A. Nicoll ECDC 2 nd WHO GAP mtg 12-14 July 2011 Background
More information31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million
31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites
More informationDrug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD
Drug Policy and the HIV Movement SAULIUS CAPLINSKAS MD, PhD Director, Lithuanian AIDS Centre Assoc. Prof., Mykolas Romeris University 14th ECAD Mayors Conference Fighting Against Drugs - From Different
More informationSyphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Syphilis Key facts In 2015, 28 701 syphilis cases were reported in 29 EU/EEA Member States (data were not available from Austria and Liechtenstein),
More information